

6TH AHOS – 03 -06 OF OCTOBER 2019–TURKEY

03 OCTOBER 2019, THURSDAY	
17:00-17:30	Registrations – Coffee
17:30-18:00	AHOS 2019-Opening remarks
	<p>Summary of the five previous AHOS: 2014 (Athens), 2015 (Chios), 2016 (Thessaloniki), 2017 (Rhodes), and 2018 (Porto Heli) / Agenda of the 6th AHOS</p> <p>Guray Saydam, TR – Evangelos Terpos, GR</p>
18:00-19:30	SESSION 1: MYELODYSPLASTIC SYNDROMES
Moderators:	Osman Ilhan,TR - Nora-AthinaViniou,GR
Debate:	NGS in the diagnosis and prognosis of MDS
Speaker:	Yes: Mehmet Ali Ozcan,TR No: Georgia Kaiafa,GR
Lecture:	Treatment of lower risk MDS after the failure of ESAS
Speaker:	Vassiliki Pappa,GR
19:30-20:00	Treatment of benign platelet disorders
Moderator:	Meltem Aylı,TR
Speaker:	Itır Demiriz Şirinoğlu, TR
20:15	Opening Ceremony - Welcome Reception

04 OCTOBER 2019, FRIDAY	
09:00-10:30	SESSION 2- Common Symposium of Balkan Myeloma Study Group and AHOS: Practical Considerations for Frontline Therapy
Moderators:	Hayri Ozsan,TR - Evangelos Terpos,GR
Lecture:	What is the optimal number of cycles for induction pre-ASCT?
Speaker:	Efstathios Kastritis,GR
Lecture:	Double ASCT: Suitable for all patients
Speaker:	Meral Beksac,TR
Lecture:	Maintenance therapy: which drug and for how long
Speaker:	Sosana Delimpasi,GR
10:30-11:00	Satellite Symposium (sponsored by Amgen): New Era with Carfilzomib in the Treatment of Relapsed Multiple Myeloma
Moderator:	Sami Kartı, TR
Speaker:	Ant Uzay, TR
11:00-11:30	Coffee Break
11:30-12.30	SESSION 3: ACUTE MYELOBLASTIC LEUKEMIA
Moderators:	Maria Pagoni, GR–Nil Güler, TR
Debate:	High or low intensity therapy for elderly AML patients?
Speakers:	High Intensity: Mehmet Yilmaz, TR Low Intensity: Sotiris Papageorgiou, GR
12:30-13:00	Meet the Expert - 1: Iron Chelation in Myelodysplastic Syndromes
Moderator:	Stavroula Giannouli, GR
Speaker:	Argiris Symeonidis,GR

13:00-13:30	Immunomodulatory Drugs in Fit and Unfit Relapsed Refractory Multiple Myeloma
Moderator:	Fahri Sahin, TR
Speaker:	Omur Gokmen Sevindik, TR
13:30-14:00	Meet the Expert - 2: Multidrug resistant bacteria in Hematology Clinics and BMT Units: a very serious problem all over the world
Moderator:	Pavlina Konstantinidou, GR
Speaker:	Damianos Sotiropoulos,GR
14:00-15:00	Lunch Break
15:00-16:00	Poster Session 1 - Poster View and Discussion
Moderators:	Erdal Kurtođlu,TR – Elisavet Grouzi, GR - Maria Kotsopoulou, GR (posters 1-16)
16:00-17:00	Poster Session 2 - Poster View and Discussion
Moderators:	İsmet Aydođdu,TR – Anastasia Pouli, GR - Nikolaos Giannakoulas, GR(posters 17-32)
16:00-17:00	Oral Session 1
Moderators:	Despina Mparmparoussi, GR –Duzgun Ozatli,TR
	<ol style="list-style-type: none"> 1- Nivolumab For Relapsed Or Refractory Hodgkin Lymphoma: Real-Life Experience (Burhan Ferhanoglu et al, Istanbul,Turkey) 2- Incidence And Treatment Outcome Of Lymphomas In Hiv-Infected Patients: The Greek Experience (Panagiotis Tsirigotis et al, Chaidari,Greece) 3- Audiologic Assessment in Patients with Beta Thalassemia Major Receiving Chelating Regimens in Denizli State Hospital: Single Center Experience (Gulsum Akgun Cagliyan et al, Denizli,Turkey)

6TH AHOS – 03 -06 OF OCTOBER 2019–TURKEY

	<p>4- Modulation of the IL-6/STAT3 Signaling Axis in CD4+ T Cells as a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes. (Eleftheria Lamprianidou et al, Alexandroupolis, Greece)</p> <p>5- Investigation Of The Effects Of Antifungal Drugs On Cyclosporin Blood Level In Patients With Allogeneic Stem Cell Transplantation: Single Center Experience (Ayşe Günay et al, Kayseri, Turkey)</p> <p>6- Stereotyped Subsets #2 and #169: High Order Sequence Relatedness In The Immunoglobulin Repertoire of CLL (Katerina Gemenetzi et al, Thessaloniki, Greece)</p>
17:00-18:30	SESSION 4: Non-Hodgkin's Lymphoma
Moderators:	Zahit Bolaman, TR–Nikos Harhalakis, GR
Debate:	Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting
Speakers:	YES: Maria Angelopoulou, GR NO: Elif Birtaş, TR
Lecture:	Modern Management of Follicular Lymphoma: Focus on First Relapse
Speaker:	Marie-Christine Kyrtsolis, GR
18:30-19:15	Monoclonal Antibodies in the treatment of ALL
Moderator:	Ali Unal, Tr
Speaker:	Tayfur Toptaş, Tr
19:15-20:00	Satellite Symposium (sponsored by Janssen): Ibrutinib in MCL and CLL
Moderators:	Levent Undar, TR – Şeniz Öngören, TR
Speakers	MCL :Burhan Ferhanoglu, TR- CLL :Ozan Salim, TR

05 OCTOBER 2019, SATURDAY	
09:00-10:30	SESSION 5: ACUTE LYMPHOBLASTIC LEUKEMIA
Moderators:	Filiz Vural, TR – Ioannis Kotsianidis, GR
Lecture:	Chemotherapy free strategy for ph+ ALL?
Speakers:	YES: Sinem Civriz Bozdog, TR NO: Panagiotis Tsirigotis, GR
Lecture:	Ph like ALL
Speaker:	Maria Papaioannou, GR
10:30-11:15	SESSION 6: Transplantation
Moderator:	Zafer Gulbas, TR – Ioanna Sakellari, GR
Debate:	Allo-BMT in all eligible AML FLT3+, MPN1+ patients: Yes or No
Speakers:	YES : Mutlu Arat, TR NO: Ioannis Baltadakis, GR
11:15-11:45	Coffee Break
11:45-12:30	Invited Speaker by the Organizing Universities
Moderators:	Panayiotis Panayiotidis, GR – Fahri Sahin, TR
Speaker:	Jane Apperley, UK
12:30-13:30	Satellite Symposium (sponsored by BMS): Nivolumab in Relapsed Refractory Hodgkin's Lymphoma
Moderators:	Güray Saydam, TR
Lecture:	Pre-clinical and clinical development of Nivolumab
Speaker:	Meltem Olga Akay, TR
Lecture:	Scientific data of efficacy of Nivolumab in RRHL
Speaker:	Tülin Tuğlular, TR

13:30-14:00	Lecture: Novel Proteasome Inhibitors and IMiDs combinations for Multiple Myeloma
Moderator:	Evangelos Terpos, GR
Speaker:	Eirini Katodritou,GR
14:00-15:00	Lunch Break
15:00-16:00	Poster Session 1: Poster View and Discussion
Moderators:	Cengiz Ceylan, TR –Kyriaki Kokoviadou,GR – Pavlina Marinaki, GR(posters 33-48)
16:00-17:00	Poster Session 2: Poster View and Discussion
Moderators:	Emin Kaya, TR – Anna Kioumi, GR – Emmanouel Spanoudakis, GR (posters 49-64)
16:00-17:00	Oral Session 2
Moderators:	Maria Gavriatopoulou, GR - Mahmut Tobu, TR
	<ol style="list-style-type: none"> 1- Long-term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-center Real-life Experience (Burhan Ferhanoglu et al, Istanbul,Turkey) 2- Newly Diagnosed Patients With Multiple Myeloma Receiving Asct And Consolidation With Carfilzomib, Lenalidomide And Dexamethasone (Krd) Show High Rates Of Minimal Residual Disease Negativity (Maria Gavriatopoulou et al, Athens, Greece) 3- A Glance to Infectious and Immune Complications During the Course of Chronic Lymphocytic Leukemia: Single Center Experience (Zehra Narli Ozdemir et al, Ankara, Turkey) 4- Three tRNA-Derived RNA Fragments (3' -tRF-LeuAAG/TAG, i-tRF-GluCTC, and i-tRF-ProTGG) Discriminate Smoldering from Symptomatic Multiple Myeloma Patients (Aristea-Maria Papanota et al, Athens, Greece) 5- The Evaluation Of The Clinicopathologic Characteristics Of T-Cell Non-Hodgkin's Lymphoma: A Multicenter Experience

6TH AHOS – 03 -06 OF OCTOBER 2019–TURKEY

	(Elifcan Aladag et al, Ankara, Turkey)
6-	Rituximab-Dose-Adjusted-Epoch (R-Da-Epoch) In Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl): The Combined Greek And Turkish Real-Life Experience On Outcomes And Prognostic Factors (Vassilakopoulos TP et al, Athens Greece)
17:00-17:30	Meet the Expert-3: How I treat Mediastinal Large B-cell Lymphoma?
Moderator:	Kostas Konstantopoulos, GR - Atilla Özkan, TR
Speaker:	Theodoros Vassilakopoulos, GR
17:30-19:00	PNH and New MoAbs in CLL and NHLs
Moderators:	Ridvan Ali, TR – Gülsüm Özet, TR
Lecture:	PNH: Update and current status
Speaker:	Asu Fergün Yılmaz, TR
Lecture:	Improvement of anti-CD20 MoAb: Obinituzumab
Speaker:	Ümit Yavuz Malkan,TR
Lecture:	Efficay and safety of obinituzumab in CLL
Speaker:	Birol Güvenç, TR
19:00-19:45	Invited speaker by the Co-Chairs
Moderators:	Guray Saydam, TR - Evangelos Terpos, GR
Lecture:	Mechanisms of cardiotoxicity of novel anticancer drugs
Speaker:	Ioanna Andreadou, GR
19:45-20:00	Best presentations Ceremony
	Güray Saydam, Tr – Evangelos

06 OCTOBER 2019 SUNDAY	
09:00-10:00	Oral Session 3:
Moderators:	Mehmet Sönmez TR, İrfan Yavaşoğlu TR
	<ol style="list-style-type: none"> 1- Retrospective Evaluation Of Clinical And Laboratory Characteristics Of Patients With Follicular Lymphoma (Hasan Çağrı Yıldırım et al, İzmir, Turkey) 2- Paroxysmal Nocturnal Hemoglobinuria Clone In Patients With Refractory Anemia (Demet Cekdemir et al, İzmir, Turkey) 3- Splenic Marginal Zone Lymphoma; Single Center Experience (Hale Bülbül et al, İzmir, Turkey) 4- Ibrutinib As Monotherapy For Relapsed Or Refractory Diffuse Large B Cell Lymphoma Patients: A Single Center Experience (Sumeyye Balta et al, Elazığ, Turkey) 5- Loss Of Early Response With Midostaurine: A Case With Aggressive Systemic Mastocytosis (Ayşe Uysal et al, Balıkesir, Turkey)
10:00-11:00	Oral Session 4:
Moderators:	Emre Eşkazan TR, Nur Soyer TR
	<ol style="list-style-type: none"> 1- Pomalidomide For Relapsed/Refractory Multiple Myeloma : A Single Center Retrospective Study (Serkan Ünal et al, Kocaeli, Turkey) 2- Evaluation of Patients with Adult Onset Langerhans Cell Histiocytosis: A Single Center Experience (Onur Aşık et al, Kayseri, Turkey) 3- Ibrutinib In B-Cell Lymphomas And Chronic Graft Versus Host Disease: A Single Center Experience (Aysenur Arslan et al, İzmir, Turkey)

6TH AHOS – 03 -06 OF OCTOBER 2019–TURKEY

	<p>4- Single Center Experience: Retrospective Evaluation of Patients with Primary Mediastinal Large B-Cell Lymphoma (Zeynep Tuğba Güven et al, Kayseri, Turkey)</p> <p>5- Nivolumab Treatment For Hodgkin Lymphoma: Ege Hematology Experience (Fatma Keklik Karadağ et al, İzmir, Turkey)</p> <p>6- Response Of Ruxolitinib To Reduce Spleen Size And Other Effectors Of This Response, One Centre Experience (Aydan Akdeniz et al, Mersin, Turkey)</p>
11:00-11:15	Closing Remarks
	Eirini Katodriotu GR – Fahri Şahin Tr